Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome P-450 CYP2C9

Thrombosis and Haemostasis

Volumn 90, Issue 1, 2003, Pages 161-162

  Zarza, José ^a   Hermida, José ^b   Montes, Ramón ^b   Páramo, José Antonio ^b   Rocha, Eduardo ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 2C9; CYTOCHROME P450 2C9 3; FRESH FROZEN PLASMA; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; TETRAZEPAM; UNCLASSIFIED DRUG; VITAMIN K GROUP;

AGED; ANTICOAGULATION; CASE REPORT; CEREBROVASCULAR ACCIDENT; DRUG POTENTIATION; DUODENUM BLEEDING; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; LETTER; LOW BACK PAIN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL;

EID: 0038298486     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613616     Document Type: Letter

References (9)

1. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119 (Suppl 1): 22S-38S.
2. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119 (Suppl 1): 108S-21S.
3. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-19.
4. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-78.
5. Hermida J, Zarza J, Alberca I, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on acenocoumarol sensitivity. Blood 2002; 99: 4237-39.
6. Tassies D, Freire C, Pijoan J, et al. Pharmacogenetics of acenocoumarol: Cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica. 2002; 87: 1185-91.
7. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
8. Verstuyft C, Morin S, Robert A, et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics. 2001; 11: 735-7.
9. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002; 12: 101-9.